SNORD75: A Small Nucleolar RNA as a Drug Target and Biomarker

Target Name: SNORD75

NCBI ID: G692195

SNORD75

Other Name(s): small nucleolar RNA, C/D box 75 | Small nucleolar RNA, C/D box 75 | U75

SNORD75: A Small Nucleolar RNA as a Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in the nucleus. One of the key functions of snRNA is to help maintain the stability of the nucleolar complex, a complex of RNA molecules that helps to ensure the proper functioning of the nuclear genome. Mutations in the snRNA gene have been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, identifying potential drug targets and biomarkers for these conditions is of great interest.

In this article, we will focus on SNORD75, a small nucleolar RNA that has been identified as a potential drug target and biomarker for various diseases. We will explore the structure and function of SNORD75, its role in the regulation of gene expression, and its potential as a drug target.

Structure and Function

SNORD75 is a 24.5 kilobase (kb) RNA molecule that contains 1,942 nucleotides. It belongs to the C/D box class of snRNAs, which have a characteristic conserved core structure that includes a 1'-end region that is usually involved in the formation of a stable RNA structure and a 3'-end region that is involved in the formation of a stable RNA-protein complex. The C/D box region of SNORD75 contains a unique feature that is characteristic of this class of snRNAs, known as the \"D-box,\" which is a region of 115 nucleotides that is involved in the formation of a stable RNA structure.

SNORD75 plays a critical role in the regulation of gene expression in the nucleus. It is one of the components of the nucleolar complex, which is a complex of RNA molecules that helps to ensure the proper functioning of the nuclear genome. The nucleolar complex includes a variety of snRNAs, including rRNA, snRNA, and scRNA, which each have distinct functions in maintaining the stability of the nuclear genome.

SNORD75 is involved in the regulation of gene expression by binding to specific protein factors that are associated with the target gene. This interaction between SNORD75 and its protein partners is known as post-transcriptional regulation (PTR). PTR is a well-established mechanism of gene regulation, in which changes in the levels of RNA molecules are directly proportional to changes in the levels of the protein factors that interact with them.

SNORD75 has been shown to play a role in the regulation of gene expression in various organisms, including humans. Studies have shown that SNORD75 is involved in the regulation of gene expression in cancer cells, where it has been shown to play a role in the development and progression of various types of cancer.

Drug Targeting

SNORD75 has been identified as a potential drug target due to its involvement in the regulation of gene expression and its role in the development of various diseases. One of the main goals of drug targeting is to identify small molecules that can interact with specific proteins and disrupt their function. This can lead to the development of new treatments for diseases that are currently difficult to treat.

SNORD75 has been shown to interact with several protein factors, including Ku70, a protein that is involved in the regulation of DNA replication, and hnRNP A28, a protein that is involved in the regulation of gene expression. These interactions suggest that SNORD75 may be a useful target for drugs that are designed to disrupt the function of these protein factors.

Biomarker

SNORD75 has also been identified as a potential biomarker for various diseases. The detection and quantification of SNORD75 levels in biological samples, such as patient tissue or fluids, can be used as a

Protein Name: Small Nucleolar RNA, C/D Box 75

The "SNORD75 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD75 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets